Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
The device is designed for early and accurate diagnosis of obstructive airway diseases such as COPD, and Asthma
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
India faces a significant and growing burden of chronic respiratory diseases such as asthma, chronic obstructive pulmonary disease
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
Clinical studies conducted in India demonstrated that this nebulized triple therapy rapidly improves lung function and offers better control of breathlessness
Subscribe To Our Newsletter & Stay Updated
